Osteochondroma, the most common benign bone tumor, may occur as a sporadic lesion or as multiple neoplasms in the context of multiple osteochondromas syndrome. The most severe complication is malignant transformation into peripheral secondary chondrosarcoma. Although both benign conditions have been linked to defects in EXT1 or EXT2 genes, contradictory reports are present in the literature regarding the requirement of their biallelic inactivation for osteochondroma development. A major limitation of these studies is represented by the small number of samples available for the screening. Taking advantage of a large series of tissues, our aim was to contribute to the definition of a genetic model for osteochondromas onset and transformation. EXT genes point mutations and big deletions were analyzed in 64 tissue samples. A double hit was found in 5 out of 35 hereditary cases, 6 out of 16 chondrosarcomas and 2 recurrences; none of the 11 sporadic osteochondromas showed two somatic mutations. Our results clearly indicate that, in most cases, biallelic inactivation of EXT genes does not account for osteochondromas formation; this mechanism should be regarded as a common feature for hereditary osteochondromas transformation and as an event that occurs later in tumor progression of solitary cases. These findings suggest that mechanisms alternative to EXT genetic alteration likely have a role in osteochondromas pathogenesis.
Introduction
Osteochondroma or osteocartilaginous exostosis is a cartilage-capped benign bony neoplasm, which mainly arises in the juxta-epiphyseal regions of long bones of affected individuals (Solomon, 1964) . Osteochondromas may occur as non-familial, sporadic lesions (solitary osteochondroma, SO) or as multiple neoplasms in the context of multiple osteochondroma hereditary syndrome (MO (MIM 133700, 133701) ).
SO are estimated to affect approximately 1-2% of the general population; they typically develop from early childhood to the end of adolescence and represent approximately 85% of all osteochondromas. Factors, such as radiation, iterated trauma, retinoid therapy and genetic defects have been suggested to contribute to the development of SO (Essadki et al., 2000) .
MO is the most common genetic skeletal dysplasia, with an estimated prevalence of 1/50 000 and an autosomal dominant inheritance (Schmale et al., 1994) . Patients with MO show multiple benign osteochondromas that usually develop gradually until puberty and are characterized by the same anatomical and histological appearance of SO (Porter and Simpson, 1999) . MO is a clinically heterogeneous disease with a great variability in size and number of osteochondromas; complications include different grade of pain, skeletal deformities, range of motion limitations, fractures and nerve compression (Hennekam, 1991) . The most severe complication of osteochondroma is the malignant transformation into secondary peripheral chondrosarcoma (PCS), which develops within the cartilage cap of a pre-existing osteochondroma (see Springfield et al., 1996 for a review). Malignant transformation of SO is rare (o1%), whereas it is estimated to occur in 1-5% of cases of MO (Hennekam, 1991; Schmale et al., 1994; Wicklund et al., 1995) .
Both conditions have been linked to genetic alterations in two main loci, EXT1 on chromosome 8q24.11-q24.13 (MIM 608177) and EXT2 on chromosome 11p12-p11 (MIM 608210) (Wu et al., 1994; Wuyts et al., 1995; Ludecke et al., 1997) . Exostosin-1 (EXT1) and exostosin-2 (EXT2) belong to the larger EXT family of homologous genes; their products, EXT1 and EXT2, are ubiquitously expressed glycoproteins with glycosyltransferase activity involved in the GAG(HS) chain elongation of heparan sulfate proteoglycans (HSPGs) (McCormick et al., 1998) . Extracellular matrix heparan sulfate proteoglycans have a fundamental role during cartilage development and skeletal growth by regulating gene expression, presentation of growth factors, establishment of morphogen gradients and modulation of blood homeostasis (Farach-Carson et al., 2005) .
The most common class of mutations in EXT1 and EXT2 consist of inactivating mutations (frame shift, nonsense and splice-site) that represent 77-80% of the MO causing mutations (Wuyts and Van Hul, 2000; Jennes et al., 2009) . These alterations determine a premature termination of encoded EXT proteins, inducing a rapid inactivation and degradation with a final result of a nearly complete loss of their function (Wuyts et al., 1998; Cheung et al., 2001) . Missense mutations are less frequent and cluster mainly in residues that are crucial for proper functioning of the EXT proteins (McCormick et al., 2000; Cheung et al., 2001) .
In the past, osteochondroma has been regarded as a perversion in the direction of normal bone growth resulting from aberrant epiphyseal development (Huvos, 1991) . However, later studies detected cytogenetic aberrations suggesting that loss or mutation of EXT1 and EXT2 are important in the pathogenesis of sporadic as well as hereditary osteochondromas, thus indicating the neoplastic origin of these lesions (Mertens et al., 1994; Bridge et al., 1998) . In 1995, two separated studies found loss of heterozygosity for markers linked to EXT1 and EXT2, and suggested that osteochondromas development follows the Knudson's two-hit model for tumor suppressor gene inactivation Raskind et al., 1995) . In this model, a germ line mutation (first hit) causes the predisposition for a disease and the somatic inactivation of the remaining wild-type copy of the gene (second hit) leads to the abnormal growth (Knudson, 1971) .
Currently, contradictory reports are present in the literature regarding the requirement of a complete inactivation of EXT genes for osteochondroma development. In 1999, Bove´e et al. found loss of heterozygosity at the EXT1 locus in three of eight SO and two of six MO cases (Bove´e et al., 1999a, b) ; more recently, the same group reported of EXT1 homozygous deletions in seven of eight SO by array-CGH and multiplex ligation-dependent probe amplification (MLPA) analysis (Hameetman et al., 2007) . In a study performed on 12 MO and 4 SO, Hall et al. found only one solitary case in which two somatic mutations were present, concluding that available data indeed provided limited support for the two-hit hypothesis (Hall et al., 2002) .
To address this, we analyzed the mutational status of EXT1/EXT2 in a series of MO, SO and PCS samples larger than all case studies reported thus far; we report germline and somatic mutational analysis of 11 sporadic and 35 hereditary osteochondromas, along with 18 PCS including 2 tumor recurrences. Our findings indicate that, in most cases, EXT genes biallelic inactivation does not account for osteochondromas onset, paving the way to future studies aimed at identifying alternative pathogenetic mechanisms and their contribution.
Results

Selection of tissue samples
Patients were selected as described in the Subjects and methods section. A total of 64 samples from 49 patients were analyzed; the type and location of each tumor sample along with patients clinical data are summarized in Table 1 .
Mutational and copy number analysis of EXT1/EXT2 genes in sporadic osteochondroma patients As described in the 'Subjects and methods' section, we used a denaturing high-performance liquid chromatography (DHPLC)/direct sequencing and MLPA protocol that allows detection of mutations located in EXT1/ EXT2 coding regions and exon-intron junctions.
Our mutational screening did not reveal any mutations in the osteochondroma samples from five SO patients (24, 26, 28, 32 and 33) , while in the other six cases we found big deletions (patients 27, 29, 30, 31), one small deletion (patients 25) and one small insertion (patient 34) on EXT1 (Table 2) . No samples with two mutational hits were observed. Similarly, the DHPLC analysis did not detect point mutations in the five chondrosarcoma resections obtained from SO patients.
Two tumor samples (FEXST238 and CST3) showed the loss of one copy of EXT1 and EXT2 respectively by MLPA screening; in the recurrence of this latter sample (FEXST249), loss of both EXT2 alleles was found ( Table 2 ). All hemizygous and homozygous deletions were confirmed by quantitative real-time PCR (Q-PCR).
The same MLPA and Q-PCR normalized values were used both for tissue and germline DNA samples to define hemizygous or homozygous losses, similarly to previous studies (Hameetman et al., 2007) . In fact, we reckon that sensitivity of these techniques, along with high tissue specificity offered by microdissection procedure, may allow us to detect similar values for germline or somatic genetic losses (Traeger-Synodinos, 2006; Hameetman et al., 2007) .
Mutational and copy number analysis of EXT1/EXT2 genes in MO patients Table 3 describes the results of our mutational screening of 35 MO tissue samples, obtained from 23 patients, and 11 PCSs along with 1 tumor recurrence from 11 subjects; germline mutations detected in related constitutional DNA samples are also listed.
In all MO and chondrosarcoma samples, the germline mutation was confirmed; all these variants have been included in the online MOs Mutation Database (Jennes et al., 2009) . 30 out of 35 MO cases showed only this heterozygous mutation, while in five tissues a double hit was found. In particular, in two MO samples (FEXST53 and FEXST218B) the germline frameshift mutation was found in homozygosity, while two resections (FEXST137 and FEXST218A) showed an additional somatic mutation (frameshift or nonsense mutation respectively) on the same gene affected by the germline alteration. MLPA analysis of these MO Moreover, for patients 5, 12, 17, 19 and 20 multiple tissue samples from different affected sites were available for analysis; among these, only one out of five (for patient 5) and two out of six (for patient 17) osteochondromas derived from a same subject were shown to carry multiple mutations (Table 4) .
We then analyzed the mutational status of 11 MOderived PCS resections (Table 3) ; our DHPLC/MLPA screening showed the presence of a somatic EXT1/2 mutational hit in four cases. In samples from patients 11, 36 and 44, the mutations detected in constitutional DNA were found at homozygous status in the tumor resections; only for sample CST2 this was due to the deletion of the wild-type allele. One PCS sample (CST1) with the EXT2 germline mutation c.124delA showed also the deletion of the first two exons of EXT1. It is important to note that the benign lesion from patient 11 (FEXST119t), unlike the malignant resection obtained from the same subject (FEXST119c), presented only the germline genetic alteration.
The screening of sample CST12, representing a tumor recurrence from the same patient of FEXST11, showed homozygosity for the germline mutation on EXT2 gene because of deletion of the wild-type allele.
Discussion
The aim of this study was to evaluate whether the occurrence of a second mutational hit in EXT genes is actually required for the development of sporadic and hereditary osteochondromas and/or for their neoplastic transformation into chondrosarcoma. In fact, the debate on the possible role of EXT1/2 as classical tumor suppressor genes, and thus the necessity of their complete inactivation for osteochondroma onset, is still open in the literature.
To address this issue, we analyzed the genetic status of EXT genes in a wide series of sporadic and hereditary osteochondromas and PCS, analyzing both point mutations and big rearrangements by DHPLC/direct sequencing and MLPA, respectively. The appropriate resolution of this latter technique to detect small homozygous deletions in osteochondroma tissue samples has recently been reported (Hameetman et al., 2007) . In this study, all MLPA results were further validated by Q-PCR.
The analysis of 11 SO tissue samples identified in five of them the deletion of one copy of EXT1 gene or part of it; this observation is in agreement with previous studies reporting that small or big deletions of EXT1 are the most common alteration in SO (Bove´e et al., 1999a, b; Bernard et al., 2001; Hameetman et al., 2007) , while single-base pair mutations are indeed rare (1 out of 11 SO samples in the present analysis). No mutations were found for 5 of 11 SOs (45%), with a percentage of negative SO similar to those reported from other authors (Hall et al., 2002; Trebicz-Geffen et al., 2008) . In spite of the size of SO series here analyzed and the methods used are comparable to those of previous reports (Bove´e et al., 1999a, b; Hameetman et al., 2007) , our screening did not evidence the presence of second mutational events that would substantiate the need of a complete EXT inactivation for nonhereditary osteochondromas development. Actually, considering the percentage of SO without EXT mutations described in this and previous studies (Hall et al., 2002; TrebiczGeffen et al., 2008) , also the presence of a first alteration on EXT1/2 does not seem to be a rule, suggesting possible alternative mechanisms for SO pathogenesis. Moreover, according to the double-hit model, each osteochondroma from a same patient requires a somatic mutation to develop; this was not confirmed from the results here obtained analyzing multiple samples from five subjects, because a somatic mutation was found only in the minority of tissues. In our opinion, this finding deserves further investigations because it could be hypothesized that these osteochondromas actually represent tumors progressing toward PCS.
Loss of heterozygosity at the EXT loci has been described in chondrosarcomas arising within the If not specified, the somatic mutation affects the same EXT gene carrying the germline mutation.
Unraveling the role of EXT genes in osteochondroma M Zuntini et al cartilage cap of both sporadic and hereditary osteochondromas Raskind et al., 1995) . Bove´e et al. confirmed this observation and extended their study to other 10 putative tumor suppressor genes, observing a high percentage of loss of heterozygosity along with ploidy ranging from half to twice the normal DNA content (Bove´e et al., 1999a, b) . They therefore suggested that PCSs gain genetic alterations during malignant transformation. In this study, we analyzed a total of 18 PCS, 5 arising within SOs and 11 MO-related, along with 2 tumor recurrences. In only two PCS from sporadic exostosis, the somatic loss of one copy of EXT1 or EXT2 gene was detected by MLPA analysis; interestingly, the corresponding recurrence of this latter sample showed the loss of both EXT2 alleles. These results indicate that in PCS from sporadic osteochondromas a double hit in EXT genes is not a common event; instead, new genetic alterations appear in the tumor recurrence, suggesting that there is a progressive accumulation of mutations involving these genes during neoplastic progression. The mutational status of these samples is remarkable also considering the rarity of mutations affecting EXT2 described so far in SO samples.
EXT genes mutation analysis performed on 11 MOrelated chondrosarcomas and one tumor recurrence confirmed the presence, in all tissues, of the germline mutations detected in correlated constitutional DNA samples. In addition, in approximately 40% of PCS samples (4 out of 11) a second somatic mutational hit was detected, substantiating the observation that multiple genetic alterations of EXT genes accumulate during malignant transformation of hereditary osteochondromas (Porter and Simpson, 1999; Bove´e et al., 1999a, b) .
To gain a critical and complete interpretation of these results, it should be considered that our genetic screening focused on coding regions and exon-intron junctions, while regulatory elements and untranslated regions were not analyzed. Therefore, we can not rule out the possibility that rare mutations occurring in these sequences were missed, although they may be infrequent (Lonie et al., 2006; Jennes et al., 2009) .
A possible limitation of our study is actually represented by the lack of information regarding the percentage of non-mutated cells that may be present in the analyzed cartilage tissues. However, although the assessed sensitivity for point mutation detection in mosaics of cells may vary according to different mutation types, the techniques used in this study can detect very low levels of mosaic mutations, such as 5% of mutated cells for DHPLC and 15% for direct sequencing (Rohlin et al., 2009 ).
In conclusion, relevance of this study is represented by the analysis of a comprehensive case study that allowed us to trace back the EXT mutations from chondrosarcomas and recurrences samples to osteochondromas and constitutional DNA. Our results clearly indicate that biallelic inactivation of EXT1 or EXT2 genes does not account for both SO and MO formation in the majority of cases. In fact, in approximately 85% of MO samples here analyzed only germline mutations were found, without additional somatic events, and 45% of SO resulted negative to our molecular screening. The presence of double hits in the EXT genes should instead be regarded as a common feature of MO malignant transformation and as an event that occurs later in tumor progression of SO-related PCS; however, this latter observation needs to be confirmed in a wider series of chondrosarcomas and recurrences samples.
All these evidences strongly suggest that, in most osteochondromas, mechanisms alternative to EXT genetic alteration likely have a role in tumors development. These may include mutations/polymorphisms in EXT regulatory sequences as well as post-transcriptional regulation pathways; otherwise, genes involved in endochondral bone formation not belonging to EXT family may be the target of secondary genetic events or functional polymorphisms.
As we performed an accurate screening of a large number of cases, we believe that our results provide a For each osteochondroma, microdissection of cartilage cap was performed at the Pathology Department at the time of pathological evaluation and all histologic slides were reviewed by a pathologist for diagnosis confirmation (MA).
We analyzed a total of 46 osteochondromas (11 SO and 35 MO) and 18 PCS (6 derived from SO and 12 from MO); 16 of 18 PCS analyzed were primary tumors and 2 were recurrences. For five MO patients (patients 5, 12, 17, 19 and 20) , we obtained samples from multiple affected sites; moreover, for all probands with hereditary conditions blood samples were analyzed as the source of germline DNA. All patients are unrelated probands, except for patient 22 and 23 that are brothers.
This project was approved by the ethics committee of Rizzoli Orthopaedic Institute; all samples were handled in a coded manner.
DNA isolation
Genomic DNA was extracted from frozen tumor tissues and lymphocytes using GENTRA Puregene Tissue kit and QIAamp DNA Mini kit (QIAGEN GmbH, Hilden, Germany), respectively. DNA quality was checked with a NanoQuant Infinite M200 instrument (Tecan Group Ltd, Ma¨nnedorf, Switzerland) before analyses.
Mutation analysis
Complete mutational screening of EXT1/EXT2 coding regions and exon-intron junctions was performed on DNA obtained from tissues by analyzing samples with DHPLC followed by direct sequencing of samples with abnormal elution profile. The 11 coding exons of EXT1 and the 13 of EXT2, along with exonintron junctions, were PCR-amplified using primer pairs and PCR condition previously described (Pedrini et al., 2005) . The results of amplification and the presence of right sized PCR reaction products were confirmed by agarose gel electrophoresis. DHPLC analysis was carried out using the WAVE DNA Fragment Analysis System 3500HT (Transgenomic, Crewe, UK) equipped with a DNASep column (Transgenomic as already described (Pedrini et al., 2005) .
Amplification products showing abnormal elution profiles were re-amplified, purified with QIAquick PCR Purification Kit (QIAGEN GmbH) and sequenced in both forward and reverse direction using BigDye Terminator chemistry version 3.1 and ABI Prism 3100 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). The reference EXT1/2 sequences were obtained from GenBank accession numbers NM_000127.2 and NM_000401.2, respectively. Mutation numbering is based on complementary DNA, such that þ 1 is the A of the ATG initiation codon.
When regions with pathogenic mutations or polymorphisms were detected in a tissue sample, direct sequencing of the same regions was performed also on DNA from related peripheral lymphocytes. All identified mutations were compared with those reported in the literature as being disease-causing for MOs (Jennes et al., 2009 ; MOs Mutation Database: http:// medgen.ua.ac.be/LOVD). The pathogenic effect of novel mutations was confirmed by testing other family members, when available, and by screening at least 200 control chromosomes from 100 unrelated healthy individuals as previously described (Pedrini et al., 2005) .
Gene copy number evaluation by MLPA and Q-PCR MLPA analysis has been performed to detect copy number variations in all tissue and blood samples. The analyses were performed using SALSA MLPA kit for EXT1/EXT2 genes, Probemix P215, according to supplier instructions (MRCHolland, Amsterdam, The Netherlands). Each sample was analyzed in at least two independent experiments. FAM-labelled ligation products were capillary electophoresed using ABI Prism 3100 automated DNA sequencer instrument with the GeneMapper 4.0 suite (Applied Biosystems) and statistically analyzed using an Excel Spreadsheet for normalization of peaks' height and area results. Both for tumor and germline DNA, normalized values over 1.30 were considered as duplications, whereas values beyond 0.80 or 0.30 were considered as hemizygous or homozygous deletions, respectively.
MLPA results were all validated by Q-PCR performed on a Corbett RotorGene 6000 instrument using SYBR Green Dye I chemistry (RT 2 Real Time SYBR Green PCR Mix, SABiosciences, Frederick, MD, USA). The DDCt method for relative quantitation was optimized using carefully designed specific primers to estimate copy numbers of all EXT1/EXT2 exons (primers sequences are available on request); the method was validated by the accurate measure of previously characterized DNA samples from blood of MO patients harboring exon copy number variations. Human b-actin (NC_000007.12) was used as endogenous control; DNA from healthy individuals was used as calibrator (DDCt ¼ 1; DDCt for deleted exons ¼ 0.5; DDCt for duplicated exons ¼ 2).
